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Pharmacokinetic immunosuppressive drug monitoring poorly correlates with clinical outcomes after 
solid organ transplantation. A promising method for pharmacodynamic monitoring of tacrolimus (TAC) 
in T cell subsets of transplant recipients might be the measurement of (phosphorylated) p38MAPK, 
ERK1/2 and Akt (activated downstream of the T cell receptor) by phospho-specific flow cytometry. Here, 
blood samples from n = 40 kidney transplant recipients (treated with either TAC-based or belatacept 
(BELA)-based immunosuppressive drug therapy) were monitored before and throughout the first year 
after transplantation. After transplantation and in unstimulated samples, p-p38MAPK and p-Akt were 
inhibited in CD8+ T cells and p-ERK in CD4+ T cells but only in patients who received TAC-based therapy. 
After activation with PMA/ionomycin, p-p38MAPK and p-AKT were significantly inhibited in CD4+ and 
CD8+ T cells when TAC was given, compared to pre-transplantation. Eleven BELA-treated patients had 
a biopsy-proven acute rejection, which was associated with higher p-ERK levels in both CD4+ and CD8+ 
T cells compared to patients without rejection. In conclusion, phospho-specific flow cytometry is a 
promising tool to pharmacodynamically monitor TAC-based therapy. In contrast to TAC-based therapy, 
BELA-based immunosuppression does not inhibit key T cell activation pathways which may contribute 
to the high rejection incidence among BELA-treated transplant recipients.
Pharmacokinetic monitoring of the most frequently used immunosuppressive drug after solid organ transplan-
tation, tacrolimus (TAC), is most often based on whole-blood, pre-dose concentrations. The TAC pre-dose con-
centration, however, has an imperfect correlation (rs ≈ 0.7) with the total exposure to TAC during a dosing 
interval as measured by the area-under the concentration versus time-curve1–3. As a consequence, and due to a 
high intra-patient variability in TAC exposure, the occurrence of acute rejection or side effects is not accurately 
predicted by TAC pre-dose concentrations4–7.
T cells are the main target of most immunosuppressive drugs used in transplantation. T cells become acti-
vated upon three separate stimulation signals: 1) antigen recognition by the T cell receptor (TCR) with the help 
of antigen presenting cells (APC); 2) co-stimulation, of which the interaction between CD28 molecules on T 
cells and CD80/86 molecules on the APC is the best known pathway, and 3) binding of cytokines8. This will 
activate intracellular signaling pathways downstream of the TCR [including the calcineurin, Mitogen-Activated 
Protein Kinase (MAPK) and PI3K pathways] and initiate the activation of transcription factors that regulate 
the production of cytokines (e.g. IL-2, IFN-γ and TNF-α)9. The activation of these pathways is characterized by 
(de-)phosphorylation of specific signaling molecules: Nuclear Factor of Activated T cells (NFAT), p38MAPK, 
Extracellular signal-Regulated Kinases 1 and 2 (ERK1/2) and AKT8 virus oncogene cellular homolog (Akt) (see 
also Supplementary Figure S1)10–14.
A promising approach to determine the biological effects of immunosuppressive drugs may be the meas-
urement of intracellular signaling pathway activation4,15–19. Several research groups have tried to find suitable 
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biomarkers for pharmacodynamic immunosuppressive drug monitoring, such as NFAT-regulated gene expres-
sion20–22. Up until now, these methods have not found their way into routine clinical practice23–26.
Phospho-specific flow cytometry of the intracellular signaling molecules p38MAPK, ERK and Akt is a prom-
ising technique to monitor the pharmacodynamic effects of immunosuppressive drugs in whole-blood of kid-
ney transplant patients27. Previous studies on phospho-specific flow cytometry have demonstrated that TAC can 
inhibit p38MAPK in a dose-dependent manner in kidney transplant patients28. Moreover, mycophenolic acid 
(MPA) was been found to decrease the phosphorylation of p38MAPK and ERK1/2 in vitro29. However, these 
previous studies lacked an appropriate control group that did not receive TAC and could therefore not exclude 
an effect of other, concomitantly used immunosuppressive drugs on T cell activation in these kidney transplant 
patients.
Belatacept (BELA), a fusion protein consisting of the Fc-fragment of human immunoglobulin G1 linked to the 
extracellular domain of human cytotoxic T-lymphocyte antigen (CTLA)-4, was approved in 2011 for the preven-
tion of acute rejection after kidney transplantation30–32. It blocks the co-stimulation signal between CD80/86 and 
CD28 molecules (on APCs and T cells, respectively) and prevents T cell activation. In contrast to TAC, BELA is 
not nephrotoxic and has less metabolic side effects, although the incidence of acute rejection with a BELA-based 
treatment is relatively high33,34. The higher risk of acute rejection of patients who receive treatment with BELA 
has been associated with a more aggressive T cell-mediated allogeneic response33,35–37. One of the explanations 
for this phenomenon is the fact that memory CD8+ T cells lack CD28 expression and are not dependent on the 
co-stimulatory signal from CD80/8635,38–40.
Here, we expand on our previous work and investigated the phosphorylation status of 3 signaling proteins 
involved in T cell activation, namely p38MAPK, ERK and Akt, by means of phospho-specific flow cytometry 
to investigate whether this technique can be used as a tool for pharmacodynamic monitoring of TAC-based 
immunosuppression after kidney transplantation28. Phosphorylation was measured in blood samples of kidney 
transplant patients treated with either a TAC-based or a BELA-based immunosuppressive regimen as a part of 
a randomized controlled clinical trial34. Both groups received MPA and prednisolone. Because BELA only indi-
rectly inhibits T cell activation, the BELA-treated group served as a control group in this study, circumventing 
a limitation of previous studies28,29. In contrast to previous studies, the effect of TAC and BELA was also deter-
mined in different CD3+ T cell subsets and at multiple time points after transplantation.
Results
Patient demographics and graft survival. Baseline patient characteristics and information regarding 
patient and graft survival are shown in Supplementary Tables S2 and S334. In summary, three patients in the BELA 
group lost their graft at day 12 (Banff type IIB acute rejection), day 59 (Banff type III acute rejection) and day 161 
(Banff type IIB acute rejection) after transplantation. The total incidence of biopsy-proven acute rejection (BPAR) 
in this group was 55% (n = 11, median time to rejection 81 days). The incidence of BPAR was lower in the TAC-
treated group (n = 2, 10%, median time to rejection 56 days). In the TAC group, one patient died 294 days after 
transplantation, due to a traumatic head injury. For the present study, patients with a BPAR were censored from 
the moment of rejection onwards, because measurements of intracellular signaling pathways after the occurrence 
of rejection were likely to be heavily influenced by the anti-rejection therapy.
T cell subset counts and immunosuppressive drug pre-dose concentrations. Figure 1a repre-
sents a gating strategy example of the phospho-specific flow cytometry measurements and the selection of the 
CD3+ T cell subsets. Absolute numbers of CD3+, CD4+, CD8+, CD4+CD28+, CD4+CD28−, CD8+CD28+ and 
CD8+CD28− T cells were constant over time after transplantation (Fig. 1b). There were no differences between 
the absolute T cell counts of TAC- and BELA-treated patients (Fig. 1b).
TAC pre-dose concentrations decreased over time and followed the targeted pre-dose concentration range 
(see Supplementary Table S4). Likewise, MPA pre-dose concentrations and prednisolone doses were in the range 
specified by the protocol. BELA was administered according to the less-intensive regimen (10 mg/kg at days 0, 4, 
30 and 90 and 5 mg/kg at days 180 and 36034. CD86 saturation of monocytes was complete at all time points of all 
BELA-treated patients34.
Whole blood phospho-specific flow cytometry of p38MAPK, ERK and Akt. Phosphorylation of 
intracellular signaling molecules was measured with or without PMA/ionomycin stimulation to monitor the 
effects of the immunosuppressive drug combination therapy, consisting of either TAC or BELA in combination 
with prednisolone and MMF. An example of the phosphorylation measurements is depicted in Fig. 2a. In the total 
CD3+ T cell population, p-p38MAPK, p-ERK and p-Akt showed significantly higher MFI values after stimulation 
(before transplantation; mean MFI: 1308, 718 and 813, respectively) compared to the isotype controls (mean MFI: 
394, 177 and 387, respectively; p < 0.001) and unstimulated samples (mean MFI: 466, 222 and 458, respectively; 
p < 0.001) (Fig. 2b). Expression of p-p38MAPK was higher in patients before transplantation than in healthy 
controls (mean MFI: 1308 vs. 916; p < 0.01). P-p38MAPK expression in CD3+ cells significantly decreased in 
the total study population and at all measured time points after transplantation, in contrast to p-ERK and p-Akt.
Signaling protein phosphorylation in T cell subsets of TAC- and BELA-treated kidney trans-
plant patients. To assess the effect of TAC on T cell subset activation, phosphorylation of p38MAPK, ERK 
and Akt was measured before and throughout the first year after transplantation in CD4+CD28+, CD8+CD28+ 
and CD8+CD28− T cell subsets of TAC-treated patients (Fig. 3 and Supplementary Figure S5). Samples of 
BELA-treated patients were included as controls.
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In unstimulated blood samples, p-ERK was significantly inhibited in CD4+CD28+ T cells when TAC was 
given, but not in the presence of BELA (p < 0.01) (see Supplementary Figure S5). This phenomenon was not 
observed in CD8+CD28+ and CD28− cells (see Supplementary Figure S5).
After PMA/ionomycin stimulation, inhibition of signaling protein phosphorylation was found for 
p-p38MAPK and p-Akt, but not for p-ERK and only during TAC-based treatment (Fig. 3). In CD4+CD28+ cells, 
TAC-based treatment showed a decreased expression of p-p38MAPK at all time points (p < 0.05) and a reduced 
p-Akt expression at most tested time points (p < 0.01) (Fig. 3a). In the presence of BELA, reduced expression of 
p-p38MAPK in CD4+CD28+ was measured only at day 90 (p < 0.05). A comparable effect of a TAC-based immu-
nosuppressive regimen was seen in CD8+CD28+ and CD8+CD28− T cells, although p-p38MAPK and p-Akt were 
not inhibited at day 90 and 180, respectively (Fig. 3b,c). Notably, at day 360, BELA-based treatment increased the 
expression of p-ERK in CD8+CD28+ T cells (Fig. 3b).
Pharmacodynamic-pharmacokinetic interrelationship between immunosuppressive drug con-
centrations, clinical outcomes and signaling protein phosphorylation. After stimulation with 
PMA/ionomycin, no correlations were found between TAC pre-dose concentrations or MPA pre-dose concen-
trations and the phosphorylation of intracellular signaling proteins (Table 1). Also no associations were found 
between the phosphorylation of p38MAPK, ERK and Akt and patient characteristics pre-, 4 and 360 days after 
transplantation (see also Supplementary Table S6).
Association between phosphorylation patterns and acute rejection episodes of BELA-treated 
patients. The association between TAC-based therapy and the incidence of BPAR could not be analyzed since 
only two out of 20 TAC-treated patients suffered from an acute rejection. These patients suffered from a Banff 
type 1 and 2 rejection, respectively34. To investigate whether a rejection episode was associated with a change in 
phosphorylation status, blood samples of BELA-treated patients suffering from BPAR were compared with those 
who remained rejection-free. Eleven out of 20 BELA-treated patients experienced BPAR34. Of these, 1 patient 
was graded Banff type 1, 8 patients were graded Banff type 2, 1 patient was graded Banff type 3, and 1 patient suf-
fered from a mixed type rejection. Both CD4+ and CD8+ T cells of these patients revealed an increase in p-ERK 
expression at day 4 and day 90, respectively, after stimulation with PMA/ionomycin (p < 0.05) (Fig. 4, middle). In 
addition, p-ERK expression at the time of rejection was high compared to patients without a rejection. There was 
no difference in p38MAPK and Akt phosphorylation between rejectors and non-rejectors in both cell subsets.
Figure 1. Gating strategy and T cell counts after transplantation. (a) Gating strategy for the phospho-specific 
flow cytometry assay to determine the percentages of CD3+ T cells and CD4+CD28+, CD8+CD28+ and 
CD8 + CD28− T cell subsets. CD3+ cells were selected in whole blood samples and gated for their negative 
expression of CD14. Then, CD3+CD14− cells were separated for their expression of CD4 or CD8 and their 
expression of CD28 within these subpopulations. (b) Absolute numbers of CD3+ T cells and T cell subsets over 
time. TAC- (open circles) and BELA-treated (black boxes) patients showed no significant difference in T cell 
subset expression after transplantation. (Data are plotted as the mean ± SEM; n = 20 TAC-treated patients and 
n = 20 BELA-treated patients); FSC) Forward scatter; SSC) sideward scatter.
www.nature.com/scientificreports/
4SCIENTIfIC REPORts | 7: 15135  | DOI:10.1038/s41598-017-15542-y
Figure 2. Phosphorylation of p38MAPK, ERK and Akt in CD3+ T cells. (a) Example of measured median 
fluorescence intensities in CD3+ T cells for p-p38MAPK, p-ERK and p-Akt before and after transplantation (in 
both unstimulated and PMA/ionomycin stimulated samples) compared to their isotype control measurements. 
Negative values measured with flow cytometry can be explained by the compensation settings of the FACS. (b) 
Total phosphorylation (after stimulation with PMA/ionomycin) of p38MAPK (upper left), ERK (right) and Akt 
(lower left) before and after transplantation compared to isotype controls, unstimulated samples and stimulated 
samples of healthy controls. Data are plotted as box and whiskers indicating total range. In contrast to p-ERK 
and p-Akt, p-p38MAPK is inhibited in CD3+ T cells at all time points after transplantation (n = 40); *p < 0.05, 
**p < 0.01, ***p < 0.001.
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Cytokine production and phosphorylation of p38MAPK. To determine whether the pharmacody-
namic drug effects also correlated with T cell subset function, correlations were calculated between p-p38MAPK 
expression and the production of IFN-γ. Before transplantation, no correlation existed between p-p38MAPK 
expression and IFN-γ production in all tested T cell subsets. At day 90 after transplantation, a significant pos-
itive correlation was found between p-p38MAPK expression and IFN-γ production in both CD4+CD28+ and 
CD8+CD28+ T cells (Fig. 5).
Figure 3. P-p38MAPK, p-ERK and p-Akt in T cell subsets of TAC- (grey) and BELA- (white) treated patients 
after stimulation with PMA/ionomycin. (a) p-p38MAPK (left), p-ERK (middle) and p-Akt (right) within 
CD4+CD28+ T cells. P-p38MAPK and p-Akt, but not p-ERK, were significantly decreased in TAC-treated 
patients at different time points after transplantation, in contrast to BELA-treated patients. (b) p-p38MAPK 
(left), p-ERK (middle) and p-Akt (right) within CD8+CD28+ T cells. P-p38MAPK and p-Akt, but not 
p-ERK, were inhibited when TAC was given. BELA caused an increase in p-ERK at day 360. (c) p-p38MAPK 
(left), p-ERK (middle) and p-Akt (right) within CD8+CD28− T cells. Phosphorylation inhibition by TAC is 
comparable with CD8+CD28+ T cells. (Data are plotted as box and whiskers indicating total range; n = 20 TAC-
treated patients and n = 20 BELA-treated patients) *p < 0.05, **p < 0.01, ***p < 0.001.
T cell subset
p-p38MAPK p-ERK p-Akt
rp p-value rp p-value rp p-value
TAC
CD4+CD28+ −0.09 0.79 0.11 0.73 −0.08 0.82
CD8+CD28+ 0.09 0.78 −0.14 0.66 0.20 0.54
CD8+CD28− −0.02 0.96 −0.15 0.64 0.20 0.53
MPA (TAC-group)
CD4+CD28+ −0.40 0.20 0.46 0.13 0.31 0.33
CD8+CD28+ −0.37 0.24 0.32 0.31 0.37 0.23
CD8+CD28− −0.26 0.41 0.31 0.32 0.36 0.25
MPA (BELA-group)
CD4+CD28+ −0.51 0.16 −0.38 0.32 −0.28 0.47
CD8+CD28+ −0.60 0.09 −0.17 0.66 −0.32 0.39
CD8+CD28− −0.29 0.44 −0.08 0.85 −0.35 0.35
Table 1. Correlation between signaling molecule phosphorylation (stimulated) and immunosuppressive drug 
pre-dose blood concentrations at day 4 after transplantation. rp Pearson correlation coefficient.
www.nature.com/scientificreports/
6SCIENTIfIC REPORts | 7: 15135  | DOI:10.1038/s41598-017-15542-y
Discussion
Pharmacokinetic monitoring of immunosuppressive drug therapy is routinely performed in most transplant 
centers. However, the TAC pre-dose concentration does not accurately predict the occurrence of acute rejection 
after kidney transplantation2,6. Here, phospho-specific flow cytometry, a promising technique with a short turn-
around time for the pharmacodynamic measurement of immunosuppressive drug effects, was investigated15,16,41. 
The technique has been used previously for testing immunosuppressive drug responses in patients with rheuma-
toid arthritis and for the monitoring of mTOR inhibitor therapy. This technique was also studied with regard to 
TDM of TAC by our group28. However, and in contrast to the present work, in that study, only p38MAPK was 
investigated and only in CD4+ and CD8+ T cells of patients treated with TAC-based immunosuppression. Here, 
three major signaling molecules involved in T cell activation, p38MAPK, ERK and Akt, were tested as potential 
biomarkers for detecting biological drug effects of TAC in different T cell subsets and compared to a group of 
patients treated with BELA-based treatment.
In directly measured blood samples of patients treated with a TAC-based immunosuppressive regimen, 
expression of p-ERK in CD4+ T cells was decreased at almost all measured time points after transplantation, 
whereas no effect was found on p38MAPK and Akt phosphorylation. In contrast, CD8+ T cells showed no 
decrease in p-ERK but showed a lower expression of p-p38MAPK and p-Akt at day 30.
There was no decrease in p-ERK induced by TAC-based treatment after stimulation with PMA/ionomycin, 
suggesting that the ERK pathway can still be activated after transplantation, despite the inhibited expression in 
unstimulated samples. A TAC-based-treatment also affected the expression of p-p38MAPK and p-Akt in stim-
ulated CD4+CD28+, CD8+CD28+ and CD8+CD28− cells, but not to the same extent. For example, CD8+ cells 
Figure 4. Signaling protein phosphorylation in BELA-treated patients with and without BPAR. Phosphorylation 
of p38MAPK (upper graphs), ERK (middle graphs) and Akt (lower graphs) in CD4+ cells (left) and CD8+ cells 
(right) after stimulation with PMA/ionomycin is shown. BELA-treated patients suffering from an acute rejection 
(grey) episode showed a significantly higher expression of p-ERK before their rejection time point compared to 
patients without a rejection within 90 days after transplantation (black). (Data are plotted as mean ± SD; n = 11 
rejectors and n = 9 non-rejectors) *p < 0.05.
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did not show an inhibition of p38MAPK at day 90, while this molecule was significantly inhibited at all measured 
time points in CD4+ cells. P-Akt showed no significant inhibition at day 180 in all T cells subsets.
BELA blocks the co-stimulation signal between the CD80/86 molecule on APC’s and the CD28 molecule on T 
cells. This indicates that BELA only indirect affects the phosphorylation of signaling pathways in T cells. Indeed, 
no effects of BELA on signaling protein phosphorylation were noticed in both unstimulated and stimulated sam-
ples. Only at day 90, when blood samples were stimulated with PMA/ionomycin, a decrease of p-p38MAPK was 
found in CD28+ cells after treatment with BELA. This effect was not noticed in CD8+CD28− cells, indicating that 
BELA did not affect these cells. However, this effect was not observed at other time points, indicating that any 
difference between the effect of BELA on CD28+ and on the more aggressive CD28− T cells could not be detected 
with phospho-specific flow cytometry. Notably and in contrast to the TAC-treated study population, expression 
of p-ERK was increased at day 360 in the presence of BELA, reflecting immune activation.
The absence of decreased signaling protein phosphorylation during BELA-based therapy also suggests that 
p-p38MAPK and p-Akt are mainly affected by TAC. However, the significant reductions that were found during 
TAC-based treatment were small and no correlations were found between TAC pre-dose concentrations and 
p-p38MAPK. However, there could be a correlation between phosphorylation expression and peak drug concen-
trations or area under the concentration-versus time curve, but these were not measured in this study. No other 
Figure 5. Correlation between signaling protein phosphorylation and IFN-γ production by T cell subsets. (a) 
Gating strategy for the production of IFN-γ by CD4+CD28+ (left), CD8+CD28+ (middle) and CD8+CD28− 
(right) cells, in both unstimulated and stimulated samples. (b) Correlations between p-p38MAPK (upper 
graphs), p-ERK (middle graphs) and p-Akt (lower graphs) and the production of IFN-γ by CD4+CD28+ (left), 
CD8+CD28+ (middle) and CD8+CD28− (right) cells after stimulation with PMA/ionomycin. Correlations were 
calculated before transplantation and 90 days after transplantation. P-p38MAPK significantly correlated with 
the production of IFN-γ in CD8+CD28+cells at day 90 after transplantation. (n = 12 before transplantation and 
n = 15 90 days after transplantation); *p < 0.05, **p < 0.01, ***p < 0.001.
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patient baseline characteristic showed an association with the expression of p-p38MAPK, p-ERK or p-Akt, sug-
gesting that the decrease in phosphorylation was not influenced by these parameters. Downstream of the MAPK 
pathway, p-p38MAPK will initiate the transcription of the IFNG gene, which in turn will lead to the production of 
IFN-γ by T cells42,43. Here, the expression of p-p38MAPK, measured by phospho-specific flow cytometry, signif-
icantly correlated with IFN-γ production in CD8+CD28+ T cells but only after transplantation when there is less 
variation in p-p38MAPK expression due to the presence of immunosuppressive drugs. Unfortunately, IFN-γ pro-
duction was not measured at day 4 and 30 after transplantation, but the immunosuppressive drug concentrations 
were higher at day 90 compared to day 180 and 360 after transplantation suggesting that a TAC-based immuno-
suppressive drug therapy is involved in the regulation of p38MAPK phosphorylation. Altogether, the correlation 
between p-p38MAPK and the production of IFN-γ suggests that measuring phosphorylation of p38MAPK could 
be an effective manner to monitor CD8+CD28+ T cell function after transplantation.
Eleven out of 20 BELA-treated patients in this study suffered from an acute rejection34. BELA-treated patients 
suffering from a BPAR showed an increased phosphorylation of ERK after stimulation with PMA/ionomycin 
in both CD4+ and CD8+ T cells, in contrast to patients without an acute rejection episode. This observation 
was made at day 4 in CD4+ and at day 90 in CD8+ cells before the rejection episode was detected. p-ERK could 
be inhibited in the presence of a TAC-based regimen, as was measured in unstimulated samples. In contrast, 
a BELA-based treatment even increased the expression of p-ERK at day 360 after stimulation of the samples. 
Previously, a weak correlation was also found between the expression of p-ERK and antibody-mediated rejection 
biopsies of heart transplant patients44. Moreover, graft survival could be prolonged by the use of an ERK1/2 inhib-
itor as was shown in a mouse model45. Altogether, these results indicate an important role for ERK in both CD4+ 
and CD8+ T cells before an acute rejection episode is diagnosed clinically. Unfortunately, it could not be verified 
in this study whether the expression of p-ERK during a rejection episode was also increased in the presence of a 
TAC-based treatment, since only two patients in this treatment group suffered from acute rejection.
This study has other limitations, such as the small sample size and the lack of correlations between the expres-
sion of p-p38MAPK, p-ERK and p-Akt and clinical outcomes. Larger prospective cohort studies should focus 
on the phosphorylation of ERK in CD4+ and CD8+ T cells after transplantation to prove that p-ERK is a reliable 
biomarker for rejection in the presence of either a BELA- or TAC-based therapy. Such a study should also meas-
ure the total expression of ERK to ensure that any effects are due to the phosphorylation inhibition and not to 
the changed expression of the total protein. Moreover, in order to use phospho-specific flow cytometry for daily 
clinical diagnostics, the technique should be validated by using area-under the concentration versus time-curve 
values instead of pre-dose concentrations. These values could also give an explanation for the low inhibitory 
effects on signaling molecule phosphorylation at specific time points and the increase in p-ERK in BELA-treated 
patients suffering from a rejection.
In conclusion, phospho-specific flow cytometry is a promising technique to monitor the pharmacody-
namic effects of a TAC, but not BELA, -based immunosuppressive therapy after transplantation. In contrast to 
TAC-based treatment, BELA-based immunosuppression does not inhibit key T cell activation pathways, despite 
the expression of CD28, which may contribute to the high rejection incidence observed among BELA-treated 
kidney transplant recipients.
Material and Methods
Kidney transplant patients. Between January 21th, 2014 and February 19th, 2016 peripheral blood samples 
were collected from renal transplant recipients to determine the effect of a TAC- or BELA-based treatment on 
CD3+ T cell subset activation. This study was part of a randomized-controlled clinical trial that was approved 
by the Medical Ethical Committee of the Erasmus MC, University Medical Center Rotterdam (MEC-2012-
421, EudraCT #2012-003169-16, http://www.trialregister.nl/trialreg/index.asp number NTR4242, registered 
October 17th 2013)34. Detailed information about study design, interventions, outcomes, sample size and ran-
domization was previously reported by de Graav et al.34. All patients (≥18 years) described in this single center 
study received a kidney from a living donor at our institution (Erasmus MC, Department of Internal Medicine, 
Rotterdam, the Netherlands)34. Kidneys were either allocated directly or as part of the Dutch national kidney 
exchange program46. Recipients of a deceased donor kidney were not included in this study and no organs were 
procured from (executed) prisoners. All experiments were performed in accordance with relevant guidelines 
and regulations. Forty renal transplant patients were included and randomized to receive a BELA-based treat-
ment (n = 20) or TAC-based treatment (n = 20). In- and exclusion criteria were described previously34. All par-
ticipants gave written informed consent for participation in this study and for collecting their blood samples. 
On the day of transplantation and on day 4 after transplantation, patients were treated with 20 mg basiliximab 
intravenously (Simulect®, Novartis, Basel, Switzerland). During the first three post-operative days prednisolone 
was administered intravenously in a dosage of 100 mg/day. Afterwards, prednisolone was given orally in a dose 
of 20 mg and tapered to 5 mg/day by month 3 and was then continued throughout the first post-transplant year. 
Mycophenolate mofetil (MMF; Cellcept®; Roche, Basel, Switzerland) was given in a starting dose of 2000 mg/
day equally divided in two doses, and then adjusted to pre-dose concentrations (target 1.5–3.0 mg/L). Patients 
received TAC (Prograf®, Astellas Pharma Inc., Tokyo, Japan) twice a day from the day of transplantation with a 
starting dose of 0.2 mg/kg/day. Thereafter, TAC was adjusted to pre-dose concentrations: 10–15 ng/mL (week 
1–2), 8–12 ng/mL (week 3–4), and 5–10 ng/mL (from week 5 onwards). BELA-treated patients received 10 mg/
kg/day BELA (Nulojix®, Bristol-Myers Squibb, New York, USA) intravenously on the day of transplantation and 
on days 4, 15, 30, 60, and 90 after transplantation. From month 4 onwards, patients received monthly infusions 
of 5 mg/kg BELA (according to the so-called less intensive regimen)33. Heparinized blood samples were collected 
pre-transplantation and 4, 30, 90, 180 and 360 days post-transplantation or before anti-rejection therapy was 
started when an acute rejection was suspected (usually on the day of the kidney biopsy).
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Immunosuppressive drug whole-blood pre-dose concentrations. TAC and MPA whole-blood or 
plasma pre-dose concentrations, respectively, were determined in EDTA blood using the antibody-conjugated 
magnetic immunoassay on a Dimension Xpand analyzer (Siemens HealthCare Diagnostics Inc., Newark, DE) 
according to the manufacturer’s instructions. The lower and upper limits of detection of TAC were 1.5 and 30 
ng/mL and for MPA 0.5 μg/ml and 15 μg/ml, respectively. For TAC, the coefficient of variations (CV) was 15.0%, 
8.9% and 11.2% for the low, middle and high control samples, respectively. For MPA, the CV was 3.9% and 3.7%, 
for the low and high controls, respectively. Proficiency samples were obtained from the UK Quality Assessment 
Scheme (Analytical Services International Ltd, London, UK) and the laboratory successfully participates in inter-
national proficiency testing schemes.
Whole-blood phospho-specific flow cytometry. Whole-blood samples were monitored for 
the expression of phosphorylated (p-) p38MAPK, ERK and Akt according to the manufacturer’s instruc-
tions for phospho-protein analysis (BD Biosciences, San Jose, CA) and as described previously47. The CV for 
phospho-specific flow cytometry was 5.6%48. In short, 200 μl heparinized blood was stained with Brilliant Violet 
(BV) 510-labeled mouse anti-human CD3 (Biolegend, San Diego, CA), peridinin chlorophyll (PERCP)-labeled 
mouse anti-human CD4 (BD Biosciences), allophycocyanin(APC)-Cy7-labeled mouse anti-human CD8 
(Biolegend), BV421-labeled mouse anti-human CD28 (BD Biosciences) and Fluorescein Isothiocyanate 
(FITC)-labeled mouse anti-human CD14 (Serotec, Oxford, UK) for 30 minutes at 37 °C. After 15 minutes of 
staining, PMA/ionomycin (Sigma-Aldrich, Steinheim, Germany) was added to activate T cells in the remaining 
15 minutes. A final optimized concentration of 500 ng/ml and 5 μg/ml of PMA and ionomycin, respectively was 
used for samples stained for p38MAPK and Akt. 100 ng/ml PMA and 1 μg/ml ionomycin was used for ERK. 
From here, unstimulated and stimulated cells with PMA/ionomycin were considered as two different samples and 
analyzed separately. Cells were then fixed and lysed for 10 minutes with Lyse/Fix buffer (BD Biosciences) and per-
meabilized with 90% methanol for 30 minutes at −20 °C. Phycoerythrin (PE)-labeled mouse anti-p-p38MAPK 
(clone pT180/pY182), PE-labeled mouse anti-p-Akt (clone pS473) or AlexaFluor647 (AF647)-labeled mouse 
anti-p-ERK1/2 (pT202/pY204) mAB (all from BD Biosciences) were used for 30 minutes at room temperature to 
stain for the intracellular signaling pathway activation. Samples were analyzed on a FACS Canto II flow cytometer 
(BD Biosciences). Isotype controls; mouse IgG1-PE (p38MAPK and Akt, Biolegend) and mouse IgG1-AF647 
(ERK; Biolegend); served as negative controls and were included in separated tubes. Cytocalbeads (Thermo 
Scientific, Fremont, CA) were used to correct for interday-variability of the flow cytometer according to the man-
ufacturer’s instructions. Absolute numbers of CD3+, CD4+ and CD8+ cells were measured with BD multi-test 
6-colour in BD TruCount Tubes (BD Biosciences, San Jose, CA).
Cytokine production. Heparinized blood samples were activated with a final concentration of 0.5 μg/
ml PMA and 10 μg/ml ionomycin for four hours at 37 °C. Golgiplug (BD Biosciences) was added during this 
incubation to accumulate cytokines intracellularly. Subsequently, EDTA was added for 15 minutes. Cells were 
then stained with BV510-labeled mouse anti-human CD3 (Biolegend), BV421-labeled mouse anti-human CD4 
(Biolegend), APC-Cy7-labeled mouse anti-human CD8 (Biolegend) and PERCP-Cy5-labeled mouse anti-human 
CD28 (BD Biosciences) for 30 minutes at room temperature, fixed twice for 10 minutes with FACS lysing solu-
tion (BD Biosciences) and treated with permeabilization buffer II (BD Biosciences) for 10 min. FITC-labeled 
mouse anti-human IFN-γ (BD Biosciences) was used for intracellular cytokine staining for 30 minutes at room 
temperature.
Statistical Analysis. The Median Fluorescence Intensity (MFI) was measured for the phosphorylation of 
p38MAPK, ERK and Akt and data-analysis was performed with Diva-version 6.0 software (BD Bioscience). 
Negative values measured with flow cytometry can be explained by the compensation settings of the FACS and 
are displayed via hyperlog transformation49. MFI values were normalized using Cytocalbeads (Thermo Scientific). 
Statistical analysis was performed with Graph Pad Prism 5.0 (Graph Pad Software Inc., La Jolla, CA) by using 
paired and unpaired t-tests (after finding a p-value > 0.05 with the Kolmogorov-Smirnov test for normality for 
the study population). Correlations between drug concentrations and phosphorylation were calculated as the 
Pearson correlation coefficient. Associations between phosphorylation levels and co-variates were tested by linear 
regression with IBM SPSS statistics software (version 21; IBM Analytics, Chicago, Illinois, USA). Bonferroni cor-
rection was used to correct for multiple testing. A two-sided p-value < 0.05 was considered statistically significant 
and for the association calculations, two-sided p-values of <0.0042 were considered statistically significant after 
Bonferroni correction.
Data availability. All data generated or analyzed during this study are included in this published article and 
its Supplementary Information files.
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